Search
SQ-109
go.drugbank.com/drugs/DB05186InvestigationalSQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesBezisterim
go.drugbank.com/drugs/DB05212InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesHepatitis B immune globulin
go.drugbank.com/drugs/DB05276ApprovedInvestigationalLong-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. ...
Products: HEPATITIS B IMMUNOGLOBULIN P BEHRING, HEPATITIS B IMMUNOGLOBULIN P BEHRING 1000 IU/5 ML IM KULLANIMA HAZIR ENJEKTÖRDE ENJEKSİYONLUK ÇÖZELTİVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectabl...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalPimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesPalovarotene
go.drugbank.com/drugs/DB05467Approved[A244920] The ossification occurring as a result of FOP is insidious and cumulative and is provoked during flare-ups or in response to injury. … Treatment options for patients with FOP are extremely limited, although there has been substantial recent interest in novel treatments for this disease.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesTelaprevir
go.drugbank.com/drugs/DB05521ApprovedWithdrawnTelaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsApremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigationalApremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesStaurosporine
go.drugbank.com/drugs/DB02010ExperimentalAn indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)
Categories: P-glycoprotein inhibitorsXanthine
go.drugbank.com/drugs/DB02134InvestigationalA purine base found in most body tissues and fluids, certain plants, and some urinary calculi. It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine. The methylated xa...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates